Accordingly, avasimibe, an inhibitor of the cholesterol esterification enzyme ACAT1, with a good safety profile in humans, significantly empowered the anti-cancer response of CD8+ T cells in melanoma-bearing mice, despite no differences in MDSCs’ frequency [226]. This evidence concerns the gene CD8A and cancer.